Difference between revisions of "Nilutamide (Nilandron)"
Jump to navigation
Jump to search
m |
m |
||
| Line 25: | Line 25: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | [[Category: | + | [[Category:First-generation nonsteroidal antiandrogens]] |
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:FDA approved in 1996]] | [[Category:FDA approved in 1996]] | ||
Revision as of 23:06, 6 June 2023
General information
Class/mechanism: Antiandrogen, nonsteroidal. Nilutamide competitively inhibits the effects of testosterone by interacting with the androgen receptor.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Nilutamide (Nilandron) patient drug information (Chemocare)[3]
- Nilutamide (Nilandron) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1996-09-19: Initial approval in combination with surgical castration for the treatment of stage D2 metastatic carcinoma of the prostate. (Based on International Anandron Study)
Also known as
- Brand names: Anandron, Nilandron, Zandron